Lin Shen

机构：Peking University, Peking University Cancer Hospital, Shanghai University of Traditional Chinese Medicine, Longhua Hospital Shanghai University of Traditional Chinese Medicine · ORCID：0000-0002-8798-4756

发表论文 805 篇 · 总被引 28280 次 · h-index 64

代表论文

• A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma (2025 · Signal Transduction and Targeted Therapy · 被引 4)
• EMB ‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy (2025 · Cancer Science · 被引 4)
• A multifunctional biomimetic nanoplatform targeting mitochondrial dynamics and oxidative stress for heart failure therapy (2026 · Journal of Nanobiotechnology)
• Figure S3 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors (2026)
• Figure S8 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors (2026)
• Figure S6 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors (2026)